The main concept here is that MyRisk testing accepts more than one specimen type because it analyzes germline DNA and has been validated to work with DNA from both sources. Blood provides high-quality, high-quantity genomic DNA that’s routinely used for sequencing panels. Saliva offers a convenient, non-invasive collection method and, with proper stabilization, yields DNA suitable for the same kind of sequencing and analysis. Both options are considered valid because the lab has demonstrated that DNA from either source meets the necessary quality and quantity for the multi-gene hereditary cancer panel. Urine isn’t used for this test because it doesn’t reliably provide the germline DNA required for comprehensive panel analysis; it usually isn’t validated for this purpose, and the DNA obtained is not consistently adequate for accurate sequencing.

HBOC and Lynch syndrome are inherited in an autosomal dominant fashion. This means a single mutated copy of the relevant gene is enough to increase cancer risk. Because of this pattern, each first-degree relative (parent, child, or full sibling) of an affected person has a 50% chance of carrying the pathogenic variant. This makes family-based testing important: if a relative carries the mutation, they can pursue targeted surveillance and risk-reducing options; if they do not carry it, their inherited risk from these mutations is not elevated.

In this tiering system, the highest level of evidence and regulatory support for using a targeted therapy is when the drug is FDA-approved for the exact cancer being treated with that biomarker. This is what Tier IA represents—the therapy is on-label for that specific cancer, providing the strongest, most actionable evidence for use. It means there is regulatory approval and established safety and efficacy in that exact tumor context. Other tiers cover scenarios like approvals in different cancers with the same biomarker or evidence from studies that aren’t as definitive; they are informative but not as directly applicable as an on-label, cancer-specific approval.

Next-generation sequencing of DNA and RNA is the approach that provides the most comprehensive view of a tumor’s genetic material. By sequencing both the genome and the transcriptome, this method detects a wide range of alterations: DNA-level changes such as point mutations, insertions and deletions, copy number variations, and structural rearrangements, plus RNA-level information like gene expression differences and fusion transcripts. The combination of breadth and depth lets a single test profile actionable mutations, expression patterns, and potential fusions that guide targeted therapies and clinical decisions. Sanger sequencing, while highly accurate for small regions, is not practical for broad tumor profiling because it sequences only one fragment at a time, making it slow and limited in scope. Microarray analysis can assess expression levels or copy-number changes but does not provide base-by-base sequence data and cannot readily identify novel variants. Quantitative PCR is fast and sensitive but is restricted to predefined targets and cannot comprehensively survey the genome or transcriptome. So, using next-generation sequencing of DNA and RNA offers the most versatile and informative analysis for Precise Tumor’s genetic material.